Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $47.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price lifted by Barclays from $42.00 to $47.00 in a report released on Thursday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.

Other research analysts also recently issued research reports about the company. TD Cowen started coverage on Teva Pharmaceutical Industries in a report on Thursday, October 1st. They set a “buy” rating and a $55.00 price objective on the stock. JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Weiss Ratings upgraded Teva Pharmaceutical Industries from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. UBS Group increased their price objective on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a report on Friday, September 4th. Finally, Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 28th. Twelve research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.92.

Teva Pharmaceutical Industries Trading Up 0.8%

Teva Pharmaceutical Industries stock opened at $41.44 on Thursday. The company’s fifty day moving average price is $38.28 and its two-hundred day moving average price is $34.89. Teva Pharmaceutical Industries has a one year low of $18.83 and a one year high of $42.02. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67. The company has a market capitalization of $48.29 billion, a price-to-earnings ratio of 69.07, a PEG ratio of 3.85 and a beta of 0.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. The firm had revenue of $4.14 billion during the quarter. On average, analysts forecast that Teva Pharmaceutical Industries will post 2.00 earnings per share for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 7,342 shares of the stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the sale, the insider owned 8,500 shares in the company, valued at approximately $330,225. This trade represents a 46.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Roberto Mignone sold 367,600 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $39.06, for a total transaction of $14,358,456.00. The SEC filing for this sale provides additional information. Insiders have sold a total of 374,959 shares of company stock valued at $14,644,285 in the last quarter. Company insiders own 0.54% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently modified their holdings of the business. WCM Investment Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 191.4% during the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock valued at $1,157,264,000 after purchasing an additional 26,813,522 shares during the last quarter. Castle Hook Partners LP acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth $82,013,000. SEB Asset Management AB bought a new stake in Teva Pharmaceutical Industries during the first quarter valued at about $59,551,000. Assenagon Asset Management S.A. grew its holdings in Teva Pharmaceutical Industries by 128.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 3,056,017 shares of the company’s stock valued at $103,538,000 after buying an additional 1,716,315 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Teva Pharmaceutical Industries by 2.2% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company’s stock valued at $1,384,216,000 after buying an additional 1,004,941 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company develops, manufactures and distributes generic medicines, specialty pharmaceuticals, active pharmaceutical ingredients and biosimilars.

Teva’s portfolio includes medicines for conditions affecting the central nervous system, respiratory system and other therapeutic areas. Its branded and specialty products include treatments such as Copaxone for multiple sclerosis, Austedo for movement disorders, Ajovy for migraine prevention and Uzedy for schizophrenia.